Xeris Biopharma Holdings Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Revenue	266.14	203.07	163.91	110.25	49.59	20.44	Upgrade
Revenue Growth (YoY)	42.05%	23.89%	48.68%	122.32%	142.67%	650.74%	Upgrade
Cost of Revenue	41.1	36.83	28.65	22.63	13.32	9.33	Upgrade
Gross Profit	225.04	166.24	135.27	87.61	36.27	11.11	Upgrade
Selling, General & Admin	168.91	157.38	146.1	137.75	116.06	73.73	Upgrade
Research & Development	29.38	25.56	22.34	20.97	25.16	18.92	Upgrade
Amortization of Goodwill & Intangibles	10.84	10.84	10.84	10.84	0.55	-	Upgrade
Operating Expenses	209.14	193.78	179.28	169.55	141.77	92.65	Upgrade
Operating Income	15.9	-27.55	-44.01	-81.94	-105.5	-81.55	Upgrade
Interest Expense	-29.63	-30.49	-26.61	-14.1	-7.18	-10.66	Upgrade
Interest & Investment Income	4.19	5.32	4.75	2.58	0.73	1.47	Upgrade
Other Non Operating Income (Expenses)	0	0.01	0	1.76	-0.7	-0.01	Upgrade
EBT Excluding Unusual Items	-9.54	-52.7	-65.87	-91.7	-112.66	-90.75	Upgrade
Merger & Restructuring Charges	-	-	-	-	-9.66	-2	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	-	-0.41	-	Upgrade
Legal Settlements	-	-	-	-	-	1.5	Upgrade
Other Unusual Items	-6.1	-4.4	2.36	-4.38	-	-	Upgrade
Pretax Income	-15.64	-57.1	-63.5	-96.08	-122.73	-91.25	Upgrade
Income Tax Expense	-	-2.27	-1.25	-1.42	-	-0.11	Upgrade
Net Income	-15.64	-54.84	-62.26	-94.66	-122.73	-91.14	Upgrade
Net Income to Common	-15.64	-54.84	-62.26	-94.66	-122.73	-91.14	Upgrade
Shares Outstanding (Basic)	156	147	138	136	79	43	Upgrade
Shares Outstanding (Diluted)	156	147	138	136	79	43	Upgrade
Shares Change (YoY)	8.48%	6.61%	1.51%	71.62%	85.32%	63.32%	Upgrade
EPS (Basic)	-0.10	-0.37	-0.45	-0.70	-1.55	-2.14	Upgrade
EPS (Diluted)	-0.10	-0.37	-0.45	-0.70	-1.55	-2.14	Upgrade
Free Cash Flow	9.98	-37.85	-49.29	-103.42	-96.62	-80.94	Upgrade
Free Cash Flow Per Share	0.06	-0.26	-0.36	-0.76	-1.22	-1.90	Upgrade
Gross Margin	84.56%	81.86%	82.52%	79.47%	73.14%	54.35%	Upgrade
Operating Margin	5.97%	-13.56%	-26.85%	-74.32%	-212.74%	-399.05%	Upgrade
Profit Margin	-5.88%	-27.00%	-37.98%	-85.86%	-247.48%	-446.00%	Upgrade
Free Cash Flow Margin	3.75%	-18.64%	-30.07%	-93.80%	-194.84%	-396.06%	Upgrade
EBITDA	28.04	-15.48	-31.68	-69.7	-103.62	-80.08	Upgrade
EBITDA Margin	10.53%	-7.62%	-19.33%	-63.22%	-208.95%	-	Upgrade
D&A For EBITDA	12.13	12.07	12.33	12.24	1.88	1.47	Upgrade
EBIT	15.9	-27.55	-44.01	-81.94	-105.5	-81.55	Upgrade
EBIT Margin	5.97%	-13.56%	-26.85%	-74.32%	-212.74%	-	Upgrade
Revenue as Reported	266.14	203.07	163.91	110.25	49.59	20.44	Upgrade

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q